The DOI matches its Crossref record; 228 of the 231 references it cites were found in a registry or an index.
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Open accessAbstract
The worldwide prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to have reached 25% or more in adults. NAFLD is prevalent in obese individuals, but may also affect non-obese insulin-resistant individuals. NAFLD is associated with a 2- to 3-fold increased risk of developing type 2 diabetes (T2D), which may be higher in patients with more severe liver disease - fibrosis increases this risk. In NAFLD, not only the close association with obesity, but also the impairment of many metabolic pathways, including decreased hepatic insulin sensitivity and insulin secretion, increase the risk of developing T2D and related comorbidities. Conversely, patients with diabetes have a higher prevalence of steatohepatitis, liver fibrosis and end-stage liver disease. Genetics and mechanisms involving dysfunctional adipose tissue, lipotoxicity and glucotoxicity appear to play a role. In this review, we discuss the altered pathophysiological mechanisms that underlie the development of T2D in NAFLD and vice versa. Although there is no approved therapy for the treatment of NASH, we discuss pharmacological agents currently available to treat T2D that could potentially be useful for the management of NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which however could be part of the therapeutic action (lipid partitioning with the expansion of subcutaneous adipose tissue) [36].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
Vernon, G. C., Baranova, A. V., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,116
Flagged first, then by citations
3 of the 231 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Gastaldelli, 2014, Chapter 3: Pathophysiology of Prediabetes: Role of Lipotoxicity?, Volume 1, 31
Cited by
Sorted by citations
Items 201–300 of 456
Лазебник, Л. Б., & Туркина, С. В. (2021) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-194-10-5-13 · Cited by 14
Kolarić, T. O., Kizivat, T., Mihaljević, V., Zjalić, M., Bilić-Čurčić, I., Kuna, L., Smolić, R., Včev, A., Wu, G. Y., & Smolić, M. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44080239 · Cited by 15
Microfluidic 3D hepatic cultures integrated with a droplet-based bioanalysis unit
de Hoyos‐Vega, J. M., Gonzalez‐Suarez, A. M., Cedillo‐Alcantar, D. F., Stybayeva, G., Matveyenko, A. V., Malhi, H., Garcia-Cordero, J. L., & Revzin, A. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115896 · Cited by 13
Nicotinate-curcumin improves NASH by inhibiting the AKR1B10/ACCα-mediated triglyceride synthesis
Lin, X.-L., Zeng, Y., Ning, J., Cao, Z., Bu, L.-L., Liao, W.-J., Zhang, Z., Zhao, T.-J., Fu, R.-G., Yang, X., et al. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02162-5 · Cited by 14
Mercurio, G., Giacco, A., Scopigno, N., Vigliotti, M., Goglia, F., Cioffi, F., & Silvestri, E. (2025) · Nutrients · doi:10.3390/nu17071214 · Cited by 16
Non-alcoholic fatty liver disease
Abdel-Rahman, R. F. (2022) · Asian Pacific Journal of Tropical Biomedicine · doi:10.4103/2221-1691.338919 · Cited by 16
Govaere, O., Petersen, S. K., Martínez-López, N., Wouters, J., Haele, M. V., Mancina, R. M., Jamialahmadi, O., Bilkei‐Gorzo, O., Lassen, P. B., Darlay, R., et al. (2020) · Journal of Hepatology · doi:10.1016/s0168-8278(20)30598-5 · Cited by 14
Cusi, K. J., & Leiva, E. G. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000717 · Cited by 14
Self-citationBeyazal Polat, H., Beyazal, M., Arpa, M., Kızılkaya, B., Ayaz, T., Gündoğdu, Ö. L., Konur, K., Polat, Z., Beyazal Çeliker, F., & Atasoy, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103513 · Cited by 13
Vergani, M., Borella, N. D., Rizzo, M., Conti, M., Perra, S., Bianconi, E., Sani, E., Csermely, A., Grespan, E., Targher, G., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16333 · Cited by 12
Adams, L. A., Kemp, W. W., Muller, K., Powell, E. E., Roberts, S. K., Bertot, L. C., Best, S., Deed, G., Emery, J. D., HOCKING, S. L., et al. (2025) · The Medical Journal of Australia · doi:10.5694/mja2.70008 · Cited by 12
From NAFLD to HCC: Advances in noninvasive diagnosis
Xu, Q., Feng, M., Ren, Y., Liu, X., Gao, H., Li, Z., Su, X., Wang, Q., & Wang, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115028 · Cited by 14
Hong, J., & Kim, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.008 · Cited by 12
The Liver in Diabetes and Metabolic Syndrome
Mahmoud, M. C., & Abdelmalek, M. F. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.04.003 · Cited by 14
Fishman, J., Tapper, E. B., Dodge, S., Miller, K., Lewandowski, D., Bogdanov, A., & Bonafede, M. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2262926 · Cited by 12
Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Lamos, E. M., Kristan, M. M., Siamashvili, M., & Davis, S. N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1917374 · Cited by 12
Semaglutide improves metabolic dysfunction‐associated steatohepatitis: A 10‐year retrospective study
Shah, P., White, M. E., Sievert, A., Conway, A., Kneepkens, A., Sayuk, G. S., Lisker‐Melman, M., & Elwing, J. E. (2024) · JGH Open · doi:10.1002/jgh3.13037 · Cited by 11
Scheithauer, T. P. M., Wortelboer, K., Winkelmeijer, M., Verdoes, X., Aydin, Ö., Acherman, Y. I. Z., de Brauw, M. L., Nieuwdorp, M., Rampanelli, E., de Jonge, P. A., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2380747 · Cited by 11
Gui, R., Ren, Y., Wang, Z., Li, Y., Wu, C., Li, X., Li, M., Li, Y., Lü, Q., & Xiong, Y. (2024) · Obesity Reviews · doi:10.1111/obr.13818 · Cited by 12
Atia, T. A., Sakr, H. I., Damanhory, A. A., Moawad, K., & Alsawy, M. (2020) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2020.1806885 · Cited by 12
Ghazanfar, H., Kandhi, S. D., Nawaz, I., Javed, N., Abraham, M. C., FARAG, M. E., Mahasamudram, J., Patel, V. B., Altaf, F., & Patel, H. (2021) · Cureus · doi:10.7759/cureus.15141 · Cited by 11
Non‐alcoholic fatty liver disease in type 2 diabetes – A specific entity?
Schröder, B., KAHL, S., & Roden, M. (2021) · Liver International · doi:10.1111/liv.14846 · Cited by 11
Abebe, G., Ayanaw, D., Mengstie, T. A., Dessie, G., & Malik, T. (2022) · SAGE Open Medicine · doi:10.1177/20503121221124762 · Cited by 11
van Dijk, A., Vali, Y., Mak, A. L., Galenkamp, H., Nieuwdorp, M., van den Born, B. H., & Holleboom, A. G. (2022) · Hepatology Communications · doi:10.1002/hep4.2109 · Cited by 11
Abdelgwad, M., Zakaria, R., Marzouk, S., Sabry, D., Ahmed, R. M., Badary, H. A., & Samir, M. (2023) · Reports of Biochemistry and Molecular Biology · doi:10.52547/rbmb.11.4.614 · Cited by 11
Ciccarelli, G., Giuseppe, G. D., Cinti, F., Moffa, S., Mezza, T., & Giaccari, A. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3668 · Cited by 11
Targher, G., & Byrne, C. D. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2020.71 · Cited by 11
SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era
Grigoriou, K., Karakasis, P., Nasoufidou, A., Stachteas, P., Klisic, A. N., Karagiannidis, E., Fyntanidou, B., Popovic, D. S., Patoulias, D., Antoniadis, A. P., et al. (2025) · Medicina · doi:10.3390/medicina61111903 · Cited by 14
Pramanik, S., Pal, P., & Ray, S. (2024) · World Journal of Methodology · doi:10.5662/wjm.v14.i2.91319 · Cited by 12
Bezafibrate Reduces Elevated Hepatic Fumarate in Insulin-Deficient Mice
Frankó, A., Irmler, M., Prehn, C. P., Heinzmann, S. S., Schmitt‐Kopplin, P., Adamski, J., Beckers, J., von Kleist-Retzow, J., Wiesner, R. J., Häring, H., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10030616 · Cited by 10
de Sousa, M. C., Delangre, E., Berthou, F., Harane, S. E., Maeder, C., Fournier, M., Krause, K., Gjorgjieva, M., & Foti, M. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101126 · Cited by 9
Heo, Y. J., Park, J., Lee, N., Choi, S., Jeon, J. Y., Han, S. J., Kim, D. J., Lee, K. W., & Kim, H. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094054 · Cited by 10
Clinical Value and Role of miR-129-5p in Non-Alcoholic Fatty Liver Disease
Wang, Y., Feng, Y., Li, H., Zhang, H., Niu, Q., Liang, K., & Bian, C. (2021) · Hormone and Metabolic Research · doi:10.1055/a-1587-9211 · Cited by 9
Kohut, T. J., & Panganiban, J. A. (2021) · JPGN Reports · doi:10.1097/pg9.0000000000000141 · Cited by 9
Shinde, S., Nelson, D. R., Mitroi, J., Heaton, P. C., Hincapie, A. L., & Brouwers, B. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2279676 · Cited by 11
Kaur, M., Murugesan, S., Singh, S., Uy, K. N., Kaur, J., Mann, N., & Sekhon, R. K. (2023) · Cureus · doi:10.7759/cureus.50118 · Cited by 9
Examining Liver Function in Adults with Diabetes in the United States
Sakharkar, P., & Deb, S. (2021) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps31851 · Cited by 9
Lautenbach, A., Wernecke, M., Mann, O., Wagner, J., Wolter, S., Stoll, F., & Aberle, J. (2022) · Obesity Surgery · doi:10.1007/s11695-022-06406-0 · Cited by 10
The Liver and the Cardiovascular System: Two of a Kind?
Francque, S. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.020286 · Cited by 9
Poljo, A., Kopf, S., Sulaj, A., Roessler, S., Albrecht, T., Goeppert, B., Bojko, S., Müller-Stich, B., & Billeter, A. (2023) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2023.07.005 · Cited by 9
Non-Alcoholic Fatty Liver Disease, Awareness of a Diagnostic Challenge—A Clinician’s Perspective
Mărginean, C. M., Pîrșcoveanu, D. F. V., Cazacu, S. M., Popescu, M. S., Mărginean, I. C., Iacob, G. A., & Popescu, M. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15040071 · Cited by 10
Migni, A., Bartolini, D., Marcantonini, G., Sardella, R., Rende, M., Tognoloni, A., Ceccarini, M. R., & Galli, F. (2025) · Journal of Pineal Research · doi:10.1111/jpi.70047 · Cited by 8
Pathogenesis and Clinical Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
Lucaciu, R. L., Coste, S. C., Hangan, A. C., Iancu, M., Orasan, O. H., Cozma, A., Bogdan, S. G., & Procopciuc, L. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125717 · Cited by 11
Kim, J., BAJAJ, H. S., Ramji, A. S., Bémeur, C., & Sebastiani, G. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.04.003 · Cited by 11
Nutrigenomics of fat-soluble vitamins and micronutrients in hepatocyte lipotoxicity and MASLD
Migni, A., Bartolini, D., Ceccarini, M. R., Galli, C., Cavaliere, G., Garetto, S., Lucci, J., & Galli, F. (2026) · Progress in Lipid Research · doi:10.1016/j.plipres.2026.101380 · Cited by 10
A nem alkoholos zsírmájbetegség és a 2-es típusú cukorbetegség.
Pár, A., Wittmann, I., & Pár, G. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32479 · Cited by 8
Apostolov, R., Wong, D. J., Low, E. S. L., Vaz, K., Spurio, J., Worland, T., Liu, D., Chan, R. K., Gow, P. J., Grossmann, M., et al. (2023) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2023.2220857 · Cited by 8
Mingrone, G., & Rajagopalan, H. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111651 · Cited by 8
Frías, J. P., Maaske, J., Suchower, L. J., Johansson, L., Hockings, P. D., Iqbal, N., & Wilding, J. P. H. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14548 · Cited by 9
Fotschki, B., Sójka, M., Kosmala, M., & Juśkiewicz, J. (2023) · Nutrients · doi:10.3390/nu15143115 · Cited by 8
Semaglutide for nonalcoholic steatohepatitis: closer to a solution?
Liava, C., & Sinakos, E. (2021) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-231 · Cited by 8
Ábel, T., Benczúr, B., & Csobod, É. C. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1458025 · Cited by 7
Ma, Y., Ma, Y., Yuan, Z. H., Han, J., Huang, D., & Qian, H. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202503076 · Cited by 7
Li, F., Li, H., Juramt, D., Kou, K., Tacke, F., & Chen, L. (2026) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2026-002343 · Cited by 8
Gignac, T., Trépanier, G., Pradeau, M., Morissette, A., Agrinier, A.-L., Larose, É., Marois, J., Pilon, G., Gagnon, C., Vohl, M., et al. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00294.2023 · Cited by 7
Golub, I. S., Manubolu, V. S., Aldana-Bitar, J., Dahal, S., Verghese, D., Alalawi, L. H., Krishnan, S., Kianoush, S., Benzing, T., Ichikawa, K., et al. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104036 · Cited by 10
State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
Cho, Y., & Lee, Y. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.102 · Cited by 7
Haudenschild, C., Vaickus, L. J., & Levy, J. (2022) · ACM Symposium on Applied Computing · doi:10.1145/3477314.3507007 · Cited by 7
Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2
Koullias, E., & Koskinas, J. S. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00564 · Cited by 7
Vitale, M., Pepa, G. D., Costabile, G., Bozzetto, L., Cipriano, P., Signorini, S. G., Leoni, V., Riccardi, G., Vaccaro, O., & Masulli, M. (2022) · Nutrients · doi:10.3390/nu14245339 · Cited by 7
Lundholm, M. D., Bena, J., Zhou, K., Tsushima, Y., & Kashyap, S. R. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108405 · Cited by 7
Scheen, A. J. (2023) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2023.100145 · Cited by 7
The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease
Tsiampali, C., Papaioannidou, P., Goulas, A., & Pοlyzos, S. A. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2274536 · Cited by 9
Smati, S., Sotin, T., Deniel, P., Ducheix, S., Joubert, M., Arnaud, L., Hadjadj, S., Cariou, B., May, C. L., & Prieur, X. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15634 · Cited by 6
Insulin increases type I collagen synthesis in hepatic stellate cells via α5β1 integrin
Dodig, M., Li, M., Dasarathy, S., Kumarasamy, S., Kasumov, T., Najjar, S. M., & McCullough, A. J. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.59 · Cited by 6
Sasaki, N., Ueno, Y., Ozono, R., Nakano, Y., & Higashi, Y. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16307 · Cited by 6
Ashi, S. I. A., Shah, R., Iftikhar, N., Lingvay, I., Kinaan, M., & Mansi, I. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16657 · Cited by 6
Liao, N.-H., Wang, C., Lai, K.-Y., Kao, H., Lin, W., & Chen, T. (2025) · Medicine · doi:10.1097/md.0000000000044109 · Cited by 6
Holleboom, A. G., Francque, S., Cusi, K. J., & Caussy, C. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100424 · Cited by 8
Self-citationStefan, N., Hartleb, M., Fan, J., Demir, M., Schattenberg, J. M., Gietka, J., Bułdak, Ł., Popovic, B., Varona, R., & Fer, B. B. D. (2026) · Liver International · doi:10.1111/liv.70601 · Cited by 6
Takahashi, J., Takahashi, N., Tadaishi, M., Shimizu, M., & Kobayashi, K. (2022) · ACS Omega · doi:10.1021/acsomega.2c06120 · Cited by 7
Inflammation in Steatotic Liver Diseases: Pathogenesis and Therapeutic Targets
Qian, S., Wang, X., Chen, Y., Zai, Q., & He, Y. (2024) · Seminars in Liver Disease · doi:10.1055/a-2338-9261 · Cited by 6
Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
Katsarou, A., Tsioulos, G., Kassi, E. N., & Chatzigeorgiou, A. (2024) · HORMONES · doi:10.1007/s42000-024-00588-1 · Cited by 8
Yang, M. J., Liu, S., Sui, Y., & Zhang, C. (2024) · Immunometabolism · doi:10.1097/in9.0000000000000047 · Cited by 6
Liu, B., Shao, T., Xiao, D., Yang, S., Lin, W., Sun, L., Zhang, W., Luo, M., Zhao, J., Yang, L., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119330 · Cited by 6
Yang, A., Jung, N., Kim, S., & Lee, J.-E. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.825141 · Cited by 6
A Review of Defatting Strategies for Non-Alcoholic Fatty Liver Disease
Young, E. N., Doğan, M., Watkins, C. E., Bajwa, A., Eason, J. D., Kuscu, C., & Kuscu, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911805 · Cited by 6
Menekşe, B., & Batman, A. (2023) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2022.0088 · Cited by 6
Chen, C., He, Y., Ni, Y., Tang, Z., & Zhang, W. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18156 · Cited by 5
Zhou, Z., Gao, N., Liu, J., Ma, X., Ge, Z., & Cheng, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70168 · Cited by 6
Heyens, L. J. M., Innocenti, F., Steenkiste, C. V., Struyve, M., Francque, S., Koek, G. H., & Robaeys, G. (2025) · Biomedicines · doi:10.3390/biomedicines13112821 · Cited by 7
Manshi, Dash, D., & Koiri, R. K. (2026) · Endocrine · doi:10.1007/s12020-026-04561-3 · Cited by 6
Fukui, H., Onishi, H., Nakamoto, A., Tsuboyama, T., Ota, T., Honda, T., Kiso, K., Yoshidome, E., Enchi, Y., Tatsumi, M., et al. (2024) · Japanese Journal of Radiology · doi:10.1007/s11604-024-01531-5 · Cited by 5
Hakkak, R., Korourian, S., Li, W., Spray, B. J., Twaddle, N. C., Randolph, C. E., Børsheim, E., & Robeson, M. S. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1487859 · Cited by 8
Mechanism of O ‐ GlcNAcylation regulating liver lipid synthesis in mice through FASN
Li, X., Zhang, Z., Zhang, M., Cao, Y., Zhou, W., Kou, L., Guo, W., Zhang, B., Li, S., & Xu, B. (2025) · The FASEB Journal · doi:10.1096/fj.202402451rr · Cited by 5
Non-alcoholic fatty liver disease and cardiovascular diseases: features of the comorbid course
Bentsa, T. М. (2020) · Medicine of Ukraine · doi:10.37987/1997-9894.2020.1(237).214176 · Cited by 5
Silva, V. M., Freitas, M., Xavier, S. A., Carvalho, P. B., Magalhães, J. T., Marinho, C. M. M., & Cotter, J. B. (2022) · GE Portuguese Journal of Gastroenterology · doi:10.1159/000527027 · Cited by 5
Waddell, T., Namburete, A. I. L., Duckworth, P., Fichera, A., Telford, A., Thomaides-Brears, H. B., Cuthbertson, D. J., & Brady, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1063882 · Cited by 5
Moss, K., Gitman, V., Pinto-Sánchez, M. I., Oczkowski, S. J. W., Armstrong, D., Jayakumar, S., Karvellas, C. J., Selzner, N., & Dionne, J. C. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-079750 · Cited by 5
Association between liver and chronic kidney disease on hemoglobin A1c concentrations
Pratt, G. W., Bi, C., Kroll, M. H., & Rao, L. V. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.04.236 · Cited by 6
Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
Kahl, S., Pützer, J., & Roden, M. (2022) · Seminars in Liver Disease · doi:10.1055/s-0041-1732354 · Cited by 5
Williams, D. M., Ali, J., Cragg, J., Ch’ng, C. L., Williams, N. W., Stephens, J. W., & Min, T. (2024) · Cureus · doi:10.7759/cureus.75993 · Cited by 4
Forst, T. M., Botz, I., Berse, M., Voswinkel, S., Strempler, M.-E., Baumann, S., & Marinez, M. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01378-z · Cited by 4
Unraveling the mechanisms of hepatogenous diabetes and its therapeutic perspectives
Yadav, M. C., Verma, S., Tiwari, P., & Mugale, M. N. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122934 · Cited by 4
Zhou, K.-B., Nie, L., Wang, M., Xiao, D.-H., Zhang, H.-Y., Yang, X., Liao, D.-F., & Yang, X. (2025) · World Journal of Stem Cells · doi:10.4252/wjsc.v17.i5.105266 · Cited by 4
Semeya, A. A., Hafez, R. S. A. A., Ewais, S. H. M., Mostafa, S. M., Eldeeb, A. A., Elgamal, R., & Othman, A. A. A. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03844-9 · Cited by 5
A collectanea of food insulinaemic index: 2023
Hendricks, S. A., Paul, M. J., Subramaniam, Y., & Vijayam, B. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.06.017 · Cited by 6
Lipid nanosystems for fatty liver therapy and targeted medication delivery: a comprehensive review
Liang, C., Liu, X., Sun, Z., Wen, L., Wu, J., Shi, S., Liu, X., Luo, N., & Li, X. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.125048 · Cited by 4
Interventions Targeting Insulin Resistance in Patients with Type 1 Diabetes: A Narrative Review
Herascu, A., Avram, V. F., Gaiţă, L., Sima, A. C., Reurean‐Pintilei, D., & Timar, B. (2024) · Medicina · doi:10.3390/medicina60122067 · Cited by 5
Saran, M., Sharma, J. K., Ranjan, A., Deka, S., Sabharwal, M., Palukari, S., & Chandolia, B. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_2212_21 · Cited by 4
Metadata
- Authors
- Gastaldelli, A., & Cusi, K.
- Affiliations
- Istituto di Fisiologia Clinica (IT)
- University of Florida (US)
- Corresponding author
- Gastaldelli, Amalia
- Cusi, Kenneth
- Venue
- JHEP Reports
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 1
- Issue
- 4
- Pages
- 312-328
- ISSN
- 2589-5559 (ISSN-L)
- PMC
- PMC7001557
- OpenAlex
- W2963543751
- Cited by
- 455
- References
- 231
- Citations by year
- 2026: 48 · 2025: 69 · 2024: 85 · 2023: 74 · 2022: 62 · 2021: 78 · 2020: 34 · 2019: 3
- FWCI
- 6.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- JHEP Reports (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Horizon H2020 (634413)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, insulin resistance, hepatic insulin sensitivity, insulin secretion, liver fibrosis, end-stage liver disease, lipotoxicity, glucotoxicity, adipose tissue dysfunction, obesity, antidiabetic drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
